Drug Design, Development and Therapy (Jan 2023)
Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes
Abstract
Sara Horst,1 Raymond K Cross2 1Vanderbilt University Medical Center, Nashville, TN, USA; 2University of Maryland School of Medicine, Baltimore, MD, USACorrespondence: Sara Horst, Vanderbilt University Medical Center, Inflammatory Bowel Disease Clinic, 719 Thompson Lane, Suite, 20500, Nashville, TN, 37204, USA, Tel +1 615-343-4758, Email [email protected]: This article will review risankizumab, a monoclonal antibody targeting interleukin 23 (IL-23) for the treatment of moderate-to-severe Crohn’s disease. The article will detail the mechanism of action and dosing strategies. Efficacy in induction and maintenances will be reviewed from available clinical trials as well as an evaluation of safety of the medication for use in Crohn’s disease and other immune mediated diseases. Finally, a discussion of when to use this medication for treatment in Crohn’s disease as well as how to monitor patients after medication initiation will be discussed.Keywords: Crohn’s disease, risankizumab, biological therapy, interleukin-23 subunit p19, remission induction
